$4.23
+0.24%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$4.24
From 52W high−18.97%
Volume1.96M
Market cap$837.99M
P/E (TTM)5.4x
P/S (TTM)4.6x
Div yield—
Key dataOct 19, 2026
Open
$4.24
From 52W high
−18.97%
Volume
1.96M
Market cap
$837.99M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
4.9x
P/E (TTM)
5.4x
RSI (14)
34.2
MomentumView details →
1D Return
+0.24%
YTD Return
−13.19%
SummaryUpdated Jun 1, 2026
Arbutus Biopharma Corporation (NASDAQ:ABUS) is a biopharmaceutical company founded in 2007 and headquartered in Warminster, Pennsylvania. Originally known as Tekmira Pharmaceuticals Corporation, the company changed its name to Arbutus Biopharma in July 2015. The company focuses on developing novel therapeutics primarily for chronic Hepatitis B virus infection, with additional research programs targeting coronaviruses including SARS-CoV-2. Arbutus has evolved from a broader drug delivery platform company into a specialized biotechnology firm with a concentrated focus on developing what it aims to be a functional cure for chronic Hepatitis B.
Similar companies
Latest newsMore news →
Arbutus Biopharma Corporation announced preliminary results of its modified Dutch auction tender offer to purchase for cancellation up to US$230 million in value of its common shares, with a tender price range of US$5.00 to US$5.75 per share, expiring September 29, 2026.20d agoArbutus Biopharma Corporation announced plans to repurchase up to US$230 million of its common shares through a modified Dutch Auction tender offer at a price between US$5.00 and US$5.75 per share, expected to commence on August 24, 2026 and expire on September 29, 2026.60d agoArbutus Biopharma reported its financial results for the second quarter of 2026, maintaining a strong financial position with cash, cash equivalents, and marketable securities of $92.6 million as of June 30, 2026.69d ago